International Journal of Clinical Oncology

, Volume 12, Issue 1, pp 31–36 | Cite as

Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer

  • Angeles Alvarez Secord
  • Laura J. Havrilesky
  • Michael E. Carney
  • John T. Soper
  • Daniel L. Clarke-Pearson
  • Gustavo C. Rodriguez
  • Andrew Berchuck
ORIGINAL ARTICLE

Abstract

Background

The purpose of this study was to evaluate the toxicity profile of weekly low-dose paclitaxel and carboplatin in patients with gynecologic malignancies.

Methods

Patients had measurable disease defined by clinical examination or radiographic studies. Each cycle of treatment consisted of carboplatin at an AUC of 2 and paclitaxel at 80 mg/m2 on days 1, 8, and 15 of a 28-day cycle.

Results

Twenty-eight patients with advanced or recurrent cervical and endometrial cancers were included in this study. The overall response rate (ORR) was 39% (2 CR, 9 PR). Among the 15 cervical cancers the ORR was 20%, while the 13 endometrial cancers had a 62% ORR. Median time to progression and overall survival was 3.4 and 7.6 months for those with cervical cancer and 5.5 and 15.4 months for those with endometrial cancer. Grade 3 or 4 hematologic toxicity was uncommon (7% grade 3 anemia, 21% grade 3 or 4 neutropenia, 7% grade 3 or 4 thrombocytopenia).

Conclusion

A regimen of weekly low-dose paclitaxel and carboplatin has an acceptable toxicity profile that is easily managed by dose adjustment and the use of erythropoietic therapy. This regimen appears to have activity in advanced or recurrent endometrial cancer which warrants further evaluation.

Key words

Endometrial cancer Cervical cancer Chemotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Cancer Society2004Cancer facts and figures 2004American Cancer SocietyAtlanta, GaGoogle Scholar
  2. 2.
    Omura, GA, Blessing, JA, Vaccarello, L,  et al. 1997Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group studyJ Clin Oncol15165171PubMedGoogle Scholar
  3. 3.
    Moore, DH, Blessing, JA, McQuellon, RP,  et al. 2004Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyJ Clin Oncol2231133119PubMedCrossRefGoogle Scholar
  4. 4.
    Ball, HG, Blessing, JA, Lentz, SS,  et al. 1996A phase II trial of taxol in advanced and recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group studyGynecol Oncol62278281PubMedCrossRefGoogle Scholar
  5. 5.
    Fleming, GF, Brunetto, VL, Cella, D,  et al. 2004Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group studyJ Clin Oncol2221592166PubMedCrossRefGoogle Scholar
  6. 6.
    Markman, M 2000Weekly paclitaxel in the management of ovarian cancerSemin Oncol23740Google Scholar
  7. 7.
    Havrilesky, LJ, Alvarez, AA, Sayer, RA,  et al. 2003Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancerGynecol Oncol885157PubMedCrossRefGoogle Scholar
  8. 8.
    Miller, AB, Hoogstraten, B, Staquet, M,  et al. 1981Reporting results of cancer treatmentCancer47207214PubMedCrossRefGoogle Scholar
  9. 9.
    Markman, M, Kennedy, A, Webster, K,  et al. 2000Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer CenterJ Clin Oncol18102105PubMedGoogle Scholar
  10. 10.
    Hoskins, PJ, Swenerton, KD, Pike, JA,  et al. 2001Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II studyJ Clin Oncol1940484053PubMedGoogle Scholar
  11. 11.
    Moller, KA, Gehrig, PA, Van Le, L,  et al. 2004The role of optimal debulking in advanced stage serous carcinoma of the uterusGynecol Oncol94170174PubMedCrossRefGoogle Scholar
  12. 12.
    Wu, CH, Yang, CH, Lee, JN,  et al. 2001Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effectsInt J Gynecol Cancer11295299PubMedCrossRefGoogle Scholar
  13. 13.
    Yu, DY, Dahl, GV, Shames, RS,  et al. 2001Weekly dosing of carboplatin increases risk of allergy in childrenJ Pediatr Hematol Oncol23349352PubMedCrossRefGoogle Scholar
  14. 14.
    Polyzos, A, Tsavaris, N, Kosmas, C,  et al. 2001Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experienceOncology61129133PubMedCrossRefGoogle Scholar
  15. 15.
    Broome, CB, Schiff, RI, Friedman, HS 1996Successful desensitization to carboplatin in patients with systemic hypersensitivity reactionsMed Pediatr Oncol26105110PubMedCrossRefGoogle Scholar
  16. 16.
    Socinski, MA, Ivanova, A, Bakri, K,  et al. 2006A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-week carboplatin and weekly paclitaxel in advanced non-small cell lung cancerAnn Oncol17104109PubMedCrossRefGoogle Scholar
  17. 17.
    Belani CP, Larocca RV, Rinaldi DA, et al. (2004) A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs standard paclitaxel and carboplatin given every 3 weeks, followed by weekly paclitaxel. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22:a7017Google Scholar
  18. 18.
    Schuette, W, Blankenburg, T, Guschall, W,  et al. 2006Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatinClin Lung Cancer7338343PubMedCrossRefGoogle Scholar
  19. 19.
    Seidman AD, Berry D, Cirrincione C, et al. (2004) CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour(h) infusion versus standard (S) 3 h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22:a512Google Scholar
  20. 20.
    Green, MC, Buzdar, AU, Smith, T,  et al. 2005Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeksJ Clin Oncol2359835992PubMedCrossRefGoogle Scholar
  21. 21.
    Rosenberg, P, Andersson, H, Boman, K,  et al. 2002Randomized trial of single agent paclitaxel given weekly versus every 3 weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinumActa Oncologica41418424PubMedCrossRefGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2007

Authors and Affiliations

  • Angeles Alvarez Secord
    • 1
  • Laura J. Havrilesky
    • 1
  • Michael E. Carney
    • 2
  • John T. Soper
    • 1
  • Daniel L. Clarke-Pearson
    • 1
  • Gustavo C. Rodriguez
    • 3
  • Andrew Berchuck
    • 1
  1. 1.Division of Gynecologic Oncology, Department of Obstetrics and GynecologyBox 3079, Duke University Medical CenterDurhamUSA
  2. 2.Division of Gynecologic Oncology, Department of Obstetrics and GynecologyUniversity of HawaiiHonoluluUSA
  3. 3.Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Evanston Northwestern Health CareNorthwestern UniversityEvanstonUSA

Personalised recommendations